Discover 1,164 paid clinical trials in Cincinnati, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
With a focus on a variety of conditions such as lymphoma, cancer, neurological diseases, and sleep apnea, Cincinnati is home to a wide array of clinical studies. The city's leading medical centers are actively recruiting participants, offering paid research opportunities for healthy volunteers or trials for specific health conditions, providing access to innovative treatments and therapies.
Filter
2
Filter results
Results: 1,164
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
for
Symptomatic Venous Thromboembolism (VTE)
Location: Cincinnati OH, Columbus OH, Indianapolis IN,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07213778
Phase3, Recruiting
Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND)
for
Breast Cancer, Surgery
Location: Cincinnati OH
Sponsor: University of Cincinnati
Sex: All
Age: 18 - 70
Code: NCT07528638
Recruiting
Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies
for
Cervical Cancer, Radiation Therapy Complication,
Location: Cincinnati OH
Sponsor: University of Cincinnati
Sex: Female
Age: 18+
Code: NCT07447895
Recruiting
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
for
Traumatic Brain Injury
Location: Cincinnati OH, Pittsburgh PA, Charlotte NC,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07455136
Recruiting
Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
for
Cystic Fibrosis
Location: Cincinnati OH
Sponsor: University of Cincinnati
Sex: All
Age: 18 - 45
Code: NCT06163482
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
for
Sickle Cell Disease Vaso-occlusive Crisis
Location: Cincinnati OH, Louisville KY, Columbus OH, Detroit MI,
Sponsor: CSL Behring
Sex: All
Age: 12+
Code: NCT06699849
Phase2, Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Location: Cincinnati OH, Columbus OH, Maumee OH, St Louis MO,
Sponsor: Tempus AI
Sex: All
Age: 0+
Code: NCT07154823
Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
for
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Location: Cincinnati OH, London, Baltimore MD, Philadelphia PA,
Sponsor: CSL Behring
Sex: All
Age: 18+
Code: NCT07094087
Phase3, Recruiting
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
for
CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia,
Location: Cincinnati OH
Sponsor: Zulfa Omer
Sex: All
Age: 18+
Code: NCT07108998
Phase2, Recruiting
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma,
Location: Cincinnati OH
Sponsor: Zulfa Omer
Sex: All
Age: 18+
Code: NCT07014917
Phase2, Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
for
Large B-cell Lymphoma, Lymphoma, B-Cell,
Location: Cincinnati OH, Louisville KY, Nashville TN, Chicago IL,
Sponsor: Lyell Immunopharma, Inc.
Sex: All
Age: 18+
Code: NCT07188558
Phase3, Recruiting
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
for
Depressive Disorder, Major
Location: Cincinnati OH, Evanston IL, Atlanta GA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 12 - 17
Code: NCT07227454
Phase3, Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer